dsm-firmenich achieves regulatory clearance in China for two HMO ingredients for early life nutrition
This approval is a significant milestone as it will create new opportunities for innovation in the field of early life nutrition and make the unique benefits of HMOs accessible to infants and young children in China.
- This approval is a significant milestone as it will create new opportunities for innovation in the field of early life nutrition and make the unique benefits of HMOs accessible to infants and young children in China.
- "We are extremely pleased to be able to announce this huge milestone for the China infant formula market and dsm-firmenich," says James Young, Vice-President of Early Life Nutrition at dsm-firmenich.
- Christoph Röhrig, Head of HNC Glycans & HMO Regulatory Affairs at dsm-firmenich added: "We followed a rigorous regulatory process to ensure all safety and health requirements were met.
- With this breakthrough approval of two of our leading HMO ingredients in China, we are now able to offer two very important HMOs to the domestic infant nutrition market."